Primary hyperaldosteronism

Experimental and Clinical Endocrinology and Diabetes

Volumn 110, Issue 6, 2002, Pages 263-271

  Quinkler, Marcus ^a   Lepenies, J ^a   Diederich, S ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Aldosterone; Conn's syndrome; Plasma renin activity; Primary hyperaldosteronism; Screening and diagnosis

Indexed keywords

6BETA IODOMETHYL 19 NORCHOLEST 5(10) EN 3BETA OL I 131; ALDOSTERONE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FELODIPINE; FLUDROCORTISONE; FUROSEMIDE; MINERALOCORTICOID RECEPTOR; NIFEDIPINE; PREDNISOLONE; RENIN; SODIUM CHLORIDE; SPIRONOLACTONE;

ADRENAL CORTEX ADENOMA; ADRENAL SCINTISCANNING; ALDOSTERONE BLOOD LEVEL; BODY POSTURE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; FAMILY HISTORY; GASTROINTESTINAL DISEASE; GYNECOMASTIA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOALDOSTERONISM; HYPOKALEMIA; IDIOPATHIC DISEASE; MASTALGIA; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROGNOSIS; PROVOCATION TEST; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SCREENING TEST; SEXUAL DYSFUNCTION; ADRENAL GLAND; BLOOD; HYPERALDOSTERONISM; PREVALENCE;

ADRENAL GLANDS; HUMANS; HYPERALDOSTERONISM; PREVALENCE; RENIN;

EID: 0036710584     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-34588     Document Type: Review

References (76)

1. Anderson GHJr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994; 12: 609-615
2. Bernini G, Moretti A, Argenio G, Salvetti A. Primary aldosteronism in normokalemic patients with adrenal incidentalomas. Eur J Endocrinol 2002; 146: 523-529
3. Biglieri EG, Schambelan M. The significance of elevated levels of plasma 18-hydroxycorticosterone in patients with primary aldosteronism. J Clin Endocrin Metab 1979; 49: 87-91
4. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan EDJr, Sos TA, Atlas SA, Muller FB, Acevedo R, Ulick S, Laragh JH. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121: 877-885
5. Bornstein SR, Stratakis CA, Chrousos GP. Adrenocortical tumors: Recent advances in basic concepts and clinical management. Ann Intern Med 1999; 130: 759-771
6. Brown RD, Wisgerhof M, Carpenter PC, Brown G, Jiang NS, Kao P, Hegstad R. Adrenal sensitivity to angiotensin II and undiscovered aldosterone stimulating factors in hypertension. J Steroid Biochem 1979; 11: 1043-1050
7. Chowdhury TA, Lasker SS. Coexisting renal artery stenosis and primary aldosteronism. Nephrol Dial Transplant 1997; 12: 2735-2736
8. Conn JW. Presidental address. I. Paintig background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17
9. Conn JW, Knopf RF. Clinical characteristics of primary aldosteronism from analysis of 145 cases. Am J Surg 1964; 107: 159-172
10. Deinum J, Derkx FH, Schalekamp MA. Improved immunoradiometric assay for plasma renin. Clin Chem 1999; 45: 847-854
11. Diederich S, Quinkler M, Hanke B, Bahr V, Oelkers W. 11β-Hydroxysteroid dehydrogenases: Key enzymes in the action of mineralocorticoids and glucocorticoids. Dtsch Med Wochenschr 1999; 124: 51-55
12. Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism (GRA): Diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids 1995; 60: 48-51
13. Fallo F, Barzon L, Biasi F, Altavilla G, Boscaro M, Sonino N. Zona fasciculata-like histotype and aldosterone response to upright posture are not related in aldosterone-producing adenomas. Exp Clin Endocrinol Diabetes 1998; 106: 74-78
14. Fallo F, Sonino N, Boscaro M, Armanini D, Mantero F, Dorr HG, Knorr D, Kuhnle U. Dexamethasone-suppressible hyperaldosteronism: Pathophysiology, clinical aspects, and new insights into the pathogenesis. Klein Wochenschr 1987; 65: 437-444
15. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: Prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867
16. Fardella CE, Pinto M, Mosso L, Gomez-Sanchez C, Jalil J, Montero J. Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene. J Clin Endocrinol Metab 2001; 86: 4805-4807
17. Farge D, Chatellier G, Pagny JY, Jeunemaitre X, Plouin PF, Corvol P. Isolated clinical syndrome of primary aldosteronism in four patients with adrenocortical carcinoma. Am J Med 1987; 83: 635-640
18. Feltynowski T, Ignatowska-Switalska H, Wocial B, Lewandowski J, Chodakowska J, Januszewicz W. Postural stimulation test in patients with aldosterone producing adenomas. Clin Endocrinol (Oxf) 1994; 41: 309-314
19. Fiad TM, Cunningham SK, Hayes FJ, McKenna TJ. Effects of nifedipine treatment on the renin-angiotensin-aldosterone axis. J Clin Endocrinol Metab 1997; 82: 457-460
20. Fohtes RG, Kater CE, Biglieri EG, Irony I. Reassessment of the predictive value of the postural stimulation test in primary aldosteronism. Am J Hypertens 1991; 4: 786-791
21. Fraser R, Beretta-Piccoli C, Brown JJ, Cumming AM, Lever AF, Mason PA, Morton JJ, Robertson JI. Response of aldosterone and 18-hydroxycorticosterone to angiotensin II in normal subjects and patients with essential hypertension, Conn's syndrome, and nontumorous hyperaldosteronism. Hypertension 1981; 3: 187-92
22. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: Plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699-705
23. Ganguly A. Current concepts - Primary aldosteronism. N Engl J Med 1998; 339: 1828-1834
24. Ganguly A. Prevalence of primary aldosteronism in unselected hypertensive populations: Screening and definitive diagnosis. J Clin Endocrinol Metab 2001; 86: 4002-4004
25. Ganguly A, Dowdy AJ, Luetscher JA, Melada GA. Anomalous postural response of plasma aldosterone concentration in patients with aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab 1973a; 36: 401-404
26. Ganguly A, Grim CE, Weinberger MH. Anomalous postural aldosterone response in glucocorticoid-suppressible hyperaldosteronism. N Engl J Med 1981; 305: 991-993
27. Ganguly A, Melada GA, Luetscher JA, Dowdy AJ. Control of plasma aldosterone in primary aldosteronism: Distinction between adenoma and hyperplasia. J Clin Endocrinol Metab 1973b; 37: 765-775
28. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FTF, Sigler PB, Lifton RP. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000; 289: 119-123
29. Gordon RD. Mineralocorticoid hypertension. Lancet 1994; 344: 240-243
30. Gordon RD. Primary aldosteronism. J Endocrinol Invest 1995; 18: 495-511
31. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Finn WL, Krek AL. Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clin Exp Pharmacol Physiol 1991; 18: 283-286
32. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315-318
33. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon: 12% Incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993; 20: 296-298
34. Guerin CK, Wahner HW, Gorman CA, Carpenter PC, Sheedy PF. 2. Computed tomographic scanning versus radioisotope imaging in adrenocortical diagnosis. Am J Med 1983; 75: 653-657
35. Hambling C, Jung RT, Gunn A, Browning MC, Bartlett WA. Reevaluation of the captopril test for the diagnosis of primary hyperaldosteronism. Clin Endocrinol (Oxf) 1992; 36: 499-503
36. Hensen J, Oelkers W. Mineralocorticoid-induced hypertension. Med Klein 1997; 92: 273-278
37. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981; 141: 1589-1593
38. Irony I, Kater CE, Biglieri EG, Shackleton CH. Correctable subsets of primary aldosteronism. Primary adrenal hyperplasia and renin responsive adenoma. Am J Hypertens 1990; 3: 576-582
39. Kaplan NM. Caution about the overdiagnosis of primary aldosteronism. Mayo Clin Proc 2001; 76: 875-876
40. Lafferty AR, Torpy DJ, Stowasser M, Taymans SE, Lin JP, Huggard P, Gordon RD, Stratakis CA. A novel genetic locus for low renin hypertension: Familial hyperaldosteronism type II maps to chromosome 7 (7p22). J Med Genet 2000; 37: 831-835
41. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355: 262-265
42. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14: 311-315
43. Lim PO, Jung RT, MacDonald TM. Is aldosterone the missing link in refractory hypertension? Aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity. J Hum Hypertens 2002; 16: 153-158
44. Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens 2001; 19: 353-361
45. Lins PE, Adamson U. Plasma aldosterone-plasma renin activity ratio. A simple test to identify patients with primary aldosteronism. Acta Endocrinol (Copenh) 1986; 113: 564-569
46. Litchfield WR, Dluhy RG. Primary aldosteronism. Endocrinol Metab Clin North Am 1995; 24: 593-612
47. Litchfield WR, New MI, Coolidge C, Lifton RP, Dluhy RG. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1997; 82: 3570-3573
48. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WFJr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-2859
49. Lyons DF, Kem DC, Brown RD, Hanson CS, Carollo ML. Single dose captopril as a diagnostic test for primary aldosteronism. J Clin Endocrinol Metab 1983; 57: 892-896
50. McKenna TJ, Sequeira SJ, Heffernan A, Chambers J, Cunningham S. Diagnosis under random conditions of all disorders of the reninangiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 1991; 73: 952-957
51. Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T, Kimura G. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999; 33: 261-266
52. Oelkers W, Diederich S, Bahr V. Primary hyperaldosteronism without suppressed renin due to secondary hypertensive kidney damage. J Clin Endocrinol Metab 2000; 85: 3266-3270
53. Pascoe L, Curnow KM, Slutsker L, Connell JM, Speiser PW, New MI, White PC. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci USA 1992; 89: 8327-8331
54. Quinkler M, Oelkers W, Diederich S. Clinical implications of glucocorticoid metabolism by 11β-hydroxysteroid dehydrogenases in target tissues. Eur J Endocrinol 2001; 144: 87-97
55. Rayner BL, Opie LH, Davidson JS. The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 2000; 90: 394-400
56. Rich GM, Ulick S, Cook S, Wang JZ, Lifton RP, Dluhy RG. Glucocorticoid-remediable aldosteronism in a large kindred: Clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med 1992; 116: 813-820
57. Shigematsu Y, Hamada M, Okayama H, Hara Y, Hayashi Y, Kodama K, Kohara K, Hiwada K. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension 1997; 29: 723-727
58. Stewart PM. Mineralocorticoid hypertension. Lancet 1999; 353: 1341-1347
59. Stewart PM, Krozowski Z. 11β-Hydroxysteroid dehydrogenase. Vitam Horm 1999; 57: 249-324
60. Stewart PM, Krozowski ZS, Gupta A, Milford DV, Howie AJ, Sheppard MC, Whorwood CB. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene. Lancet 1996; 347: 88-91
61. Stokes GS, Monaghan JC, Roche J, Grunstein H, Gordon RD. Concurrence of primary aldosteronism and renal artery stenosis. Clin Exp Pharmacol Physiol 1992; 19: 300-303
62. Stowasser M. Primary aldosteronism: Revival of a syndrome. J Hypertens 2001; 19: 363-366
63. Stowasser M, Bachmann AW, Huggard PR, Rossetti TR, Gordon RD. Treatment of familial hyperaldosteronism type 1: Only partial suppression of adrenocorticotropin required to correct hypertension. J Clin Endocrinol Metab 2000; 85: 3313-3318
64. Stowasser M, Gordon RD. Familial hyperaldosteronism. J Steroid Biochem Mol Biol 2001; 78: 215-229
65. Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T. Vascular complications in patients with aldosterone producing adenoma in Japan: Comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest 1995; 18: 370-373
66. Thibonnier M, Sassano P, Dufloux MA, Plouin PF, Corvol P, Menard J. A simple diagnostic test for primary hyperaldosteronism. Presse Med 1983; 12: 1461-1466
67. Torpy DJ, Gordon RD, Lin JP, Huggard PR, Taymans SE, Stowasser M, Chrousos GP, Stratakis CA. Familial hyperaldosteronism type II: Description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab 1998; 83: 3214-3218
68. Torpy DJ, Stratakis CA, Chrousos GP. Hyper- and hypoaldosteronism. Vitam Horm 1999; 57: 77-216
69. Trenkel S, Seifarth C, Schobel H, Hahn EG, Hensen J. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism. Exp Clin Endocrinol Diabetes 2002; 110: 80-85
70. Udelsman R, Fishman EK. Radiology of the adrenal. Endocrinol Metab Clin North Am 2000; 29: 27-42
71. Vallotton MB. Primary aldosteronism. Part I. Diagnosis of primary hyperaldosteronism. Clin Endocrinol (Oxf) 1996b; 45: 47-52
72. Vallotton MB. Primary aldosteronism. Part II. Differential diagnosis of primary hyperaldosteronism and pseudoaldosteronism. Clin Endocrinol (Oxf) 1996a; 45: 53-60
73. Weinberger MH, Fineberg NS. The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med 1993; 153: 25-29
74. Weinberger MH, Grim CE, Hollifield JW, Kem DC, Ganguly A, Kramer NJ, Yune HY, Wellman H, Donohue JP. Primary aldosteronism: Diagnosis, localization, and treatment. Ann Intern Med 1979; 90: 386-395
75. Young WFJr. Pheochromocytoma and primary aldosteronism: Diagnostic approaches. Endocrinol Metab Clin North Am 1997; 26: 801-827
76. Young WFJr, Stanson AW, Grant CS, Thompson GB, van Heerden JA. Primary aldosteronism: Adrenal venous sampling. Surgery 1996; 120: 913-920